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Abstract
Background: Cardiovascular diseases are expanding to a major social-economic burden in the Western World and
undermine man’s deep desire for healthy ageing. Epidemiological studies suggest that flavanol-rich foods (e.g. grapes, wine,
chocolate) sustain cardiovascular health. For an evidenced-based application, however, sound clinical data on their efficacy
are strongly demanded.
Methods: In a double-blind, randomized, placebo-controlled intervention study we supplemented 28 male smokers with
200 mg per day of monomeric and oligomeric flavanols (MOF) from grape seeds. At baseline, after 4 and 8 weeks we
measured macro- and microvascular function and a cluster of systemic biomarkers for major pathological processes
occurring in the vasculature: disturbances in lipid metabolism and cellular redox balance, and activation of inflammatory
cells and platelets.
Results: In the MOF group serum total cholesterol and LDL decreased significantly (P#0.05) by 5% (n=11) and 7% (n=9),
respectively in volunteers with elevated baseline levels. Additionally, after 8 weeks the ratio of glutathione to glutathione
disulphide in erythrocytes rose from baseline by 22% (n=15, P,0.05) in MOF supplemented subjects. We also observed
that MOF supplementation exerts anti-inflammatory effects in blood towards ex vivo added bacterial endotoxin and
significantly reduces expression of inflammatory genes in leukocytes. Conversely, alterations in macro- and microvascular
function, platelet aggregation, plasma levels of nitric oxide surrogates, endothelin-1, C-reactive protein, fibrinogen,
prostaglandin F2alpha, plasma antioxidant capacity and gene expression levels of antioxidant defense enzymes did not
reach statistical significance after 8 weeks MOF supplementation. However, integrating all measured effects into a global,
so-called vascular health index revealed a significant improvement of overall vascular health by MOF compared to placebo
(P#0.05).
Conclusion: Our integrative multi-biomarker approach unveiled the pleiotropic vascular health benefit of an 8 weeks
supplementation with 200 mg/d MOF in humans.
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Introduction
Cardiovascular diseases (CVD) are expanding to a major social-
economic burden in the Western World [1,2]. Despite a diverse
disease pattern in advanced states, the early onset of CVD is
characterized by the occurrence of several general pathophysio-
logical mechanisms. Persistently increased levels of inflammation
and oxidative stress, elevated serum lipid levels as well as the
development of a prothrombotic state crucially contribute to the
occurrence of an impaired vascular function [3]. Chronic cigarette
smoking is one of the lifestyle factors that essentially fuels and
exaggerates these processes. It is well established that cigarette
smoke contains large quantities of free radicals and pro-oxidant
compounds [4] and additionally increases endogenous free radical
production by the activation of macrophages and neutrophils,
uncoupling endothelial nitric oxide synthase (eNOS) and mito-
chondrial transport chain [5–7]. As a consequence markers of
oxidative stress and inflammation are significantly elevated in the
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Heightened serum lipid levels and the activation of platelets
further promote the manifestation of a proatherogenic state in
smokers [13,14] and contribute to the development of endothelial
dysfunction in coronary and peripheral conductance and resis-
tance vessels [15,16]. Furthermore, dietary antioxidants like
vitamin C have been shown to improve or even reverse
proatherogenic, proinflammatory and prothrombotic conditions
in smokers [17,18].
In search of strategies which are able to sustain long-term
cardiovascular health and are easily implementable in peoples’
everyday life, dietary supplementation may indeed offer valuable
opportunities. Epidemiological studies performed over the past
decades underpin that a traditional Mediterranean diet reduces
the risk of CVD [19,20]. Since polyphenols, in particular
monomeric and oligomeric flavan-3-ols (MOF) consisting of up
to 5 flavanol units, are an integral part of this diet, these
compounds have been widely studied in vitro and in vivo in order to
elucidate their mechanism of action to prevent CVD [21–24]. The
seeds of grapes (Vitis vinifera L.) are in particular rich in MOF.
Since grape seed extracts consist of different mixtures of MOF and
other polyphenols, a thorough analysis of their composition is
indispensable for characterizing the active principle. Moreover,
various MOF are supposed to modulate diverse (patho)physiolog-
ical processes, which requires the assessments of multiple clinical
endpoints. Beyond such multifaceted mechanisms of action,
nutrients, in contrast to drugs, are known to modulate human’s
body function in a subtle manner. As a consequence, the classical
way of proving clinical effectiveness by the assessment of a single
primary end point does not adequately reflect the mode of action
of these compounds and frequently fails to unveil significant effects
[25]. Therefore, the present pilot study aimed to investigate the
pleiotropic effects of a relatively low dose supplementation with a
well-characterized MOF composition from grape seeds in the
human vasculature in a holistic manner. The meticulous selection
of outcome parameters led to a spectrum of makers that comprised
established as well as novel cardiovascular risk factors and systemic
biomarkers reflecting the most essential pathomechanisms in the
human vasculature on a functional and (sub)cellular level. The
integration of the changes in these biomarkers into a vascular
health index enabled us to demonstrate the beneficial effects of
MOF on vascular health in general. This is the first trial that
applies an integrative biomarker approach in order to determine
the health effects of a dietary supplementation in the human
vasculature.
Methods
The protocol for this trial and CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol
S1.
Subjects and study design
The study was designed as a randomized, placebo-controlled,
double-blind trial and conducted at the Maastricht University and
Academic Hospital Maastricht, The Netherlands. Non-obese men
were eligible when they were between 30 and 60 years old and
smoked $10 cigarettes per day for at least 5 years. Exclusion
criteria were a history or presence of any metabolic, cardiovascular
and/or malignant disease, excessive consumption of alcohol (.28
consumptions, i.e. approximately 250 g/week), a vegetarian/
vegan life style, medically prescribed diet or slimming diet and
the use of any supplement and functional food containing
vitamins, antioxidants and/or polyphenolic compounds for 4
weeks before and during the study. Thirty-three eligible subjects
were included and randomized in the study (Figure S1). Five
subjects dropped out either before or after the 1
st study visit due to
personal reasons which were not related to the study.
All subjects gave their written informed consent prior to their
participation. The study was approved by the Medical Ethical
Committee of the Maastricht University and Academic Hospital
Maastricht, The Netherlands and conducted in accordance with
the World Medical Association Declaration of Helsinki of 1975 as
revised in 2008.
Subjects were randomly assigned to one of the two test groups
under taking into account that the groups became balanced with
respect to the number of cigarettes smoked per day.
The two parallel supplementation regimes consisted of capsules
containing either 100 mg MOF from Vitis vinifera L. seeds
(MASQUELIER’sH Original OPCs) or an equivalent amount of
microcrystalline cellulose (placebo). The composition of the verum
capsules regarding its standardized MOF content is shown in
Table 1. The MOF and the placebo material were provided by
International Nutrition Company (INC) BV, Loosdrecht, The
Netherlands in indistinguishable opaque capsules which were
packaged in blisters and boxes labeled with the treatment code.
Subjects and investigators were blinded for the treatment code
until data analysis was completed. The subjects were asked to daily
take 2 capsules with a glass of water in the morning directly before
breakfast and to note the time of intake in their study diary. In
addition, subjects were instructed not to change their daily eating,
smoking and life style habits and to record all potential deviations
in their study diary on a daily base. Every 2 weeks subjects were
invited for a control visit at the investigational site in order to
control their well-being and the occurrence of potential adverse
events. At these occasions a comparable number of subjects of
both test groups reported discomfort from common cold,
headache, nausea, and shoulder and ankle injury during the 8
study weeks. All these events were classified by the subjects as mild
and were not related to the intervention. The intake of the test
capsules was checked based on the entries in the study diary and
the blisters returned. These controls revealed full intake compli-
ance in both test groups (median, 100%).
The outcome parameters were measured prior to the start of the
supplementation (baseline), and after 4 and 8 weeks of supple-
Table 1. Composition of monomeric and oligomeric flavanols
isolated from grape (Vitis vinifera L.) seeds and incorporated in
the verum test capsules.
Compound Amount % (wt:wt)
Total catechins 25.6
(+)-catechin 10.9
(2)-epicatechin 12.2
(2)-epicatechin-3-O-gallate 2.5
Total dimers 27.5
proanthocyanidin B1 7.7
proanthocyanidin B2 8.3
proanthocyanidin B3 2.8
proanthocyanidin B4 1.6
proanthocyanidin B2-gallate 7.1
Total tri-, tetra- and pentameric
proanthocyanidins
46.9
doi:10.1371/journal.pone.0028460.t001
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from smoking and drinking alcohol- and/or caffeine-containing
drinks for at least 12 h in advance.
The vascular function measurements took place in a quiet, air-
conditioned room of the Academic Hospital Maastricht with a
constant temperature of 23uC.
After arrival, subjects rested in supine position for at least 15 min
beforethemeasurementscommenced.Thesequence ofthevascular
function measurements was for each subject at random, but
remained the same for every individual on the three test sessions.
Subsequent to the vascular measurements venous blood was
collected. Plasma and serum were obtained by centrifugation at
800 g and 4uC for 10 min and immediately processed as described
for the individual parameter. Plasma samples for the quantification
of the trolox equivalent antioxidant capacity (TEAC), 8-isopros-
taglandine F2a (8-iso-PGF2a), nitrate and nitrite (NOx) and
endothelin-1 (ET-1) concentrations were stored at 280uC until
analysis.
Sample size
A conclusive sample size calculation was infeasible for the effects
of an 8 weeks MOF supplementation on our primary study
parameter, i.e. vascular function assessed as either brachial artery
FMD or LDF due to a lack of effect magnitude. In persons at low
risk of coronary heart disease, an increase in FMD of 1.4%
lowered their Framingham risk by 1% [26]. Assuming a variance
of 1.8% for the change in brachial FMD, we would be able to
detect a change of 1.4% in FMD in a group of n=[2s
(za+zb)
2](mx2my)
2=15 subjects with a power of 80% (b=0.20;
zb=0.84) and an a-value of 0.05 (za=1.96) upon the MOF
supplementation.
Measurement of macrovascular function
Macrovascular function was assessed as flow-mediated dilation
(FMD) of the brachial artery in accordance with the recommen-
dations of the International Brachial Artery Reactivity Task Force
[27]. Details can be found in Text S1. FMD values were calculated
as the maximal increase in diameter relative to the baseline
diameter (in percentage).
Measurement of microvascular function
Microvascular function was assessed by measuring skin blood
flow responses by means of Laser-Doppler-flowmetry (LDF)
following iontophoretical application of 9 subsequent dosages of
either acetylcholine (ACh), a mix of ACh and L-NG-monomethyl-
arginine (L-NMMA) or sodium nitroprusside (SNP) using the
Periflux System 5000 (Perimed AB, Stockholm, Sweden). Ionto-
phoretic conditions are given in Text S1. Maximal blood flow
perfusion (in percentage of baseline blood flow) and dosage
interval resulting in half maximal blood flow response (ED50) were
determined from the accumulative blood flow response curves by
visual inspection.
Measurement of biochemical vascular parameters
Plasma NOx concentrations were determined by the Griess
method as described by Giustarini et al. [28].
Plasma ET-1 was measured by a commercially available
radioimmunoassay kit (S2024, Bachem, Switzerland) after plasma
extraction by passage through SepPak C18 cartridges (Waters,
Netherlands).
Arginase activity in erythrocytes was measured following a
modified Schimke’s method as described by Corraliza and
colleagues [29].
Measurement of serum lipid levels
Total cholesterol (tChol), low-density lipoprotein cholesterol
(LDL), high density lipoprotein cholesterol (HDL) and triglycerides
(TG) were quantified by means of enzymatic colorimetric assays
on a Roche/Hitachi Modular analyzer (Roche Diagnostics
GmbH, Mannheim, Germany).
Measurement of platelet function
Platelet function was measured in platelet-rich plasma by
classical light transmission aggregometry, using a Chronolog
aggregometer (Chrono-log Corporation, Havertown, PA, USA;
Text S1). Collagen (1.5 mg/L) induced percentage aggregation
(CPA) and rate (CPAR) as well as adenosine diphosphate (ADP,
10 mM) induced percentage aggregation (APA) and rate (APAR)
were measured in triplicate per subject and time point in the study.
Measurement of plasma fibrinogen
Fibrinogen (Fib) plasma concentrations were determined on a
STA-R Evolution analyzer (Roche Diagnostics GmbH, Mann-
heim, Germany).
Measurement of systemic inflammatory parameters
The inflammatory resistance of subjects’ blood was investigated
ex vivo as described by Swennen et al. [30], with some minor
modification (Text S1). Tumor necrosis factor (TNF)-a and
interleukin (IL)-10 were quantified by means of commercially
available ELISA kits (PeliKine Compact human ELISA kits,
CLB/Sanquin). The limits of sensitivity were 1 pg/mL for both
cytokines.
CRP serum concentrations were measured by particle-en-
hanced immunoturbidimetry on a Roche/Hitachi Modular
analyzer (Roche Diagnostics GmbH, Mannheim, Germany).
Measurement of redox state parameters
Plasma antioxidant capacity was quantified as TEAC according
to Fischer et al [31] and corrected for plasma uric acid
concentrations.
Glutathione and glutathione disulphide (GSH/GSSG) concen-
trations in erythrocytes were assessed as described by Julicher et al.
[32] and Griffith [33].
Plasma total 8-iso-PGF2a concentrations were determined after
alkaline hydrolysis and solid phase extraction by using a
commercially available enzyme immunoassay (Cayman Chemical
Company, Ann Arbor, MI, USA).
Real-time (RT)-Polymerase chain reaction (PCR)
Expression of genes coding for inflammatory mediators and
redox enzymes in whole blood were measured by real-time RT-
PCR. Details of the procedures as well as the sequences of the
primers used are available in Text S1.
Calculation of the vascular health index (VHI)
As an integrative measure of the diverse effects of the MOF
supplementation on vascular health, the VHI was established. This
index was calculated per subject after 4 and 8 weeks intervention
by adding up the percentage change from baseline of those
parameters for which it was expected that an increase indicates a
beneficial effect on cardiovascular health. The percentage change
from baseline of parameters for which it was expected that a
decrease reflects a beneficial health effect were subtracted. The
gene expression data were not taken into account, because up- or
down regulation of the assessed genes could not be unambiguously
related to health benefits. These considerations led to the
Vascular Health Benefits of Flavanols
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28460construction of the following formula:
VHI~D% FMD ðÞ {D% ED50ACh ðÞ zD% NOx ½ 
{D% ET 1 ½  {D% arginase activity ðÞ
{D% tChol ½  {D% LDL ½  zD% HDL ½ 
{D% tChol=HDL ½  {D% TG ½ 
{D% CPA ðÞ {D% CPAR ðÞ {D% APA ðÞ
{D% APAR ðÞ {D% Fib ½  {D% TNF   a ½ 
zD% IL 10 ½  {D% TNF   a=IL   10 ½ 
{D% CRP ½  zD% TEAC ðÞ
zD% GSH=GSSG ½  {D% 8 iso   PGF2a ½ 
Statistical methods
All data were tested for normal distribution by visual inspection
of the histograms, taking into account the outcomes of the
Kolmogorov-Smirnov- and Shapiro-Wilk- tests. Normally distrib-
uted data are presented as mean 6 SEM. If log-transformation did
not result in a normal distribution, data are given as median and
range (tables) or 10
th and 90
th percentiles (figures).
Changes after 4 and 8 weeks intervention with respect to
baseline were appraised within a test group by one-tailed paired-
samples t-tests in case of normally distributed data and by
Wilcoxon Signed Ranks tests in case of not normally distributed
data.
Differences between the test groups at each of the 3 time points
(baseline, 4 and 8 weeks) as well as in the changes after 4 and 8
weeks with respect to baseline were tested by two-tailed
independent samples t-tests in case of normally distributed data
and Mann-Whitney U-tests in case of not normally distributed
data. Level of significance was set at P#0.05. Statistical analyses
were performed using PASW statistics 17.0 (SPSS Inc, Chicago,
IL, USA) and GraphPad PrismH (Graphpad Software, Inc., San
Diego, CA, USA).
Results
Both test groups did not differ significantly at baseline with
respect to their anthropometric characteristics, smoking habits,
blood pressure and serum lipid concentrations (Table 2). Blood
pressure values were within the normal range and did not fluctuate
significantly over the intervention period. Eleven subjects of the
MOF group and 10 subjects of the placebo group exhibited
elevated tChol concentrations, i.e. .5 mmol/L [34]. In both
groups 9 subjects revealed LDL concentrations .3.2 mmol/L.
TG serum concentrations were within the normal range for both
groups [35].
Effects of the MOF supplementation on vascular function
Macrovascular function assessed as FMD of the brachial artery
did not differ between the MOF and the placebo group
throughout the study period (Table 4).
In addition, MOF supplementation did not affect the maximal
ACh-induced blood flow response and the maximal endothelial
nitric oxide synthase (eNOS)-mediated blood flow response, which
was obtained from the maximal blood flow induced by ACh with
and without the eNOS inhibitor L-NMMA (data not shown).
Large within-subject fluctuations of the blood flow responses upon
SNP application reduced the sensitivity of the assessment of these
data.
After 4 weeks the ED50 of ACh was one dosage interval lower in
the MOF group than in the placebo group (P,0.05) indicating an
increased sensitivity towards the endothelium-dependent vasodi-
lator ACh. However, at the end of the study the ED50 in both test
groups were not significantly different (P=0.26) (Table 4).
Effects of the MOF supplementation on biochemical
vascular parameters
No effects of the MOF supplementation on plasma nitrite,
nitrate and ET-1 concentrations as well as arginase activity in
erythrocytes were detected (Table 4).
Table 2. Clinical characteristics of the study population
1.
Time
(weeks)
MOF
(n=15)
Placebo
(n=13) P value
2
Age, y 0 46 (30–58) 48 (30–60) 0.982
BMI, kg/m
2 02 4 612 5 61 0.221
Years of smoking 0 28 (14–45) 29 (15–45) 0.982
Cigarettes/day 0 17 (10–28) 15 (9–30) 0.799
Pack years 0 19 (7–62) 18 (9–54) 0.928
SBP, mmHg 0 114 (103–124) 115 (102–149) 0.580
4 115 (101–136) 114 (100–154) 0.771
8 115 (100–134) 108 (100–150) 0.240
DBP, mmHg 0 74 (60–85) 76 (59–99) 0.695
4 71 (61–85) 74 (58–100) 0.942
8 72 (56–84) 73 (58–99) 0.645
tChol, mmol/L 0 5.7 (4.0–7.1) 5.7 (3.6–8.5) 0.945
4 5.7 (4.0–6.3) 5.5 (4.5–8.8) 0.730
8 5.9 (3.8–6.8) 5.7 (3.6–8.8) 0.800
LDL, mmol/L 0 3.860.2 3.960.3 0.890
4 3.760.2 3.860.3 0.601
8 3.860.2 3.860.3 0.821
HDL, mmol/L 0 1.260.1 1.360.1 0.418
4 1.260.1 1.460.1 0.305
8 1.260.1 1.460.1 0.190
tChol/HDL ratio 0 4.8 (2.9–8.8) 4.0 (2.9–9.5) 0.433
4 4.9 (2.6–6.1) 4.0 (2.7–8.5) 0.344
8 4.9 (2.9–7.5) 4.3 (2.8–9.8) 0.299
TG, mmol/L 0 1.2 (0.9–4.0) 1.4 (0.8–4.3) 0.872
4 1.6 (0.9–3.7) 1.5 (0.8–3.6) 0.549
8 1.6 (0.6–2.8) 1.4 (0.7–4.5) 0.533
CRP, mg/L 0 2 (0–6) 1 (0–5) 0.196
4 2 (0–10) 1 (0–6) 0.317
8 2 (0–6) 1 (0–6) 0.055
Fibrinogen, g/L 0 3.5 (2.4–4.8) 3.3 (2.8–5.3) 0.460
4 3.3 (2.4–6.3) 3.5 (2.2–4.9) 0.800
8 3.9 (2.6–5.7) 3.3 (2.7–4.6) 0.146
1Values are mean 6 SEM or median (range); BMI, body mass index; CRP, C-
reactive protein; DBP, diastolic blood pressure; HDL, high density lipoprotein;
LDL, low density lipoprotein; MOF, monomeric and oligomeric flavanols; SBP,
systolic blood pressure; tChol, total cholesterol; TG, triglycerides.
2P value for between-groups differences assessed by independent Student’s t-
test or Mann-Whitney U-test where median (range) is indicated.
doi:10.1371/journal.pone.0028460.t002
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concentrations
Serum lipid concentrations did not change significantly during
the 8 weeks intervention in both test groups (Table 2). However, in
the subgroup of individuals with baseline tChol.5 mmol/L
(n=11) MOF supplementation significantly lowered tChol by
9% after 4 weeks (P,0.05 vs. baseline) and by 5% after 8 weeks
(P=0.05 vs. baseline). In contrast, in the similar placebo subgroup
(n=10), no significant effects on tChol were seen during the study
(Figure 1A).
LDL concentrations in the subgroup with baseline levels
.3.2 mmol/L (n=9) decreased significantly by 11% after 4
weeks (P,0.05 vs. baseline) and 7% after 8 weeks MOF intake
(P,0.05 vs. baseline; Figure 1B). In relation to that, in the similar
placebo subgroup (n=9) no significant effect on LDL was
observed.
In the MOF and the placebo subgroup the tChol-HDL-ratio
did not differ significantly during the intervention (Figure 1C).
5 subjects of the MOF group and 4 of the placebo group had
TG concentrations .1.7 mmol/L, which is defined by the
American Heart Association as ‘‘borderline high’’ [35]. After 4
weeks the average TG concentrations dropped by 13% (MOF,
P=0.16 vs. baseline) and 16% (placebo, P=0.06 vs. baseline).
While in the placebo subgroup TG concentrations returned to
baseline after 8 weeks (P=0.44 vs. baseline), in the MOF subgroup
TG concentrations remained on the low 4 weeks level (P=0.31 vs.
baseline; Figure 1D).
Effects of the MOF supplementation on platelet
aggregation ex vivo and plasma fibrinogen levels
Whereas the total percentage of collagen-and ADP-induced
platelet aggregation did not change by the 8 weeks MOF
supplementation (Table 3), the rate of the collagen-induced
aggregation was lower in the MOF group than in the placebo
group after 8 weeks (P,0.01, Table 3). In contrast to this, the rate
of the ADP-induced aggregation increased significantly from
baseline in the MOF group (P,0.05).
Plasma fibrinogen concentrations were unaffected by the MOF
supplementation (Table 2).
Effects of the MOF supplementation on systemic
inflammatory parameters
Ex vivo LPS-induced release of the proinflammatory cytokine
TNF-a decreased from baseline by 14% (P,0.05) after 8 weeks
Table 3. Platelet aggregation parameters.
1
Time
(weeks)
MOF
(n=15)
Placebo
(n=13) P value
2
APA, % 0 75 (65–86) 77 (58–96) 0.872
4 74 (65–81) 71 (48–84) 0.117
8 74 (57–85) 74 (62–83) 0.835
APAR, slope 0 102 (59–135) 109 (74–133) 0.140
4 107 (62–127) 97 (83–141) 0.872
8 112 (77–139) 101 (81–138) 0.278
CPA, % 0 76 (70–81) 77 (71–96) 0.151
4 78 (65–84) 78 (71–83) 0.746
8 78 (60–81) 79 (71–82) 0.782
CPAR, slope 0 88613 94617 0.338
49 2 612 95611 0.486
88 6 612 9968 0.003
1Values are mean 6 SEM or median (range); APA, ADP-induced platelet
aggregation; APAR, ADP-induced platelet aggregation rate; CPA, collagen-
induced platelet aggregation; CPAR, collagen-induced platelet aggregation
rate.
2P value for between-groups differences assessed by independent Student’s t-
test or Mann-Whitney U-test where median (range) is indicated.
doi:10.1371/journal.pone.0028460.t003
Table 4. Macro- and microvascular function and biochemical vascular parameters.
1
Time (weeks) MOF (n=15) Placebo (n=13) P value
2
FMD, % 0 3.5 (0.9–5.8) 4.8 (0–11.8) 0.294
4 3.0 (20.8–11.5) 4.7 (1.3–10.7) 0.149
8 3.5 (0.8–5.6) 3.7 (1.9–5.2) 0.678
ED50ACh 0 5 (2–7) 5 (0–7) 0.384
4 4 (3–6) 5 (0–8) 0.039
8 4 (2–6) 3 (0–6) 0.257
NOx,mM 0 25.862.1 24.363.3 0.518
4 23.861.7 25.762.9 0.637
8 23.261.8 21.962.2 0.525
ET-1, pmol/L 0 6.6 (4.8–7.9) 6.8 (5.7–8.4) 0.322
4 6.2 (5.0–12.0) 6.3 (4.9–8.4) 0.790
8 6.3 (4.9–7.3) 6.3 (5.6–7.8) 0.596
Arg. activity, mM urea6mg protein
216h
21 0 1.6 (1.2–3.4) 1.6 (1.0–2.0) 0.627
4 1.7 (1.1–2.9) 1.4 (1.0–2.0) 0.277
8 1.7 (1.2–3.0) 1.5 (1.1–2.0) 0.391
1Values are mean 6 SEM or median (range); Arg. activity, erythrocytes’ arginase activity; ED50ACh, ACh dose interval resulting in 50% of the maximum dermal blood flow
response; ET-1, plasma endothelin-1; FMD, flow mediated dilation; MOF, monomeric and oligomeric flavanols; NOx, plasma nitrite and nitrate.
2P value for between-groups differences assessed by independent Student’s t-test or Mann-Whitney U-test where median (range) is indicated.
doi:10.1371/journal.pone.0028460.t004
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th to 90
th percentile) serum lipid concentrations after 4 and 8 wk supplementation
with either 200 mg/d monomeric and oligomeric flavanols (MOF) or placebo: (A) total cholesterol (tChol) concentrations of
subjects with tChol baseline concentrations .5.0 mmol/L (MOF group: n=11, placebo group: n=10); (B) low density lipoprotein
(LDL) concentrations of subjects with LDL baseline concentrations .3.2 mmol/L (MOF group: n=9, placebo group: n=9); (C) ratio
of tChol to high density lipoprotein (HDL) of subjects with tChol baseline concentrations .5.0 mmol/L (MOF group: n=11, placebo
group: n=10); (D) triglycerides (TG) concentrations of subjects with TG baseline concentrations .1.7 mmol/L (MOF group: n=5,
placebo group: n=4). Within-group changes were appraised by Wilcoxon Signed Ranks test, between-group changes by Mann-Whitney U test;
*Significantly different from baseline in the same group, P,0.05. There were no significant differences between the MOF and the placebo group at
the same time points.
doi:10.1371/journal.pone.0028460.g001
Vascular Health Benefits of Flavanols
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28460MOF supplementation. This reduction was also significant
compared to the placebo group at 8 weeks (P,0.05; Figure 2A).
The release of the anti-inflammatory IL-10 did not deviate
significantly from baseline in the MOF supplemented group and
was similar to the alterations observed in the placebo group.
However, the significantly lower ratio of the pro- and the anti-
inflammatory cytokine (TNF-a/IL-10: baseline median=105 vs. 8
weeks median=62, P,0.05) underlines the anti-inflammatory
effect of the MOF supplementation.
Moreover, the MOF supplementation significantly attenuated
gene expression of the cytokines IL-6 (after 4 weeks: 218%,
P,0.05 vs. baseline) as well as TNF-a (after 8 weeks: 212%,
P,0.05 vs. baseline) and IL-10 (after 8 weeks: 227%, P,0.05 vs.
baseline) in whole blood (Figure S2A, C, E). Contrary, MOF
supplementation did not alter serum CRP concentrations (Table 2)
and the expression of genes coding IL-1b and IL-8, NOS2,
nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor alpha, intercellular adhesion molecule 1 and vascular cell
adhesion molecule 1 (Figure S2B, D, F, G, H, I).
Effects of the MOF supplementation on redox state
parameters and oxidative stress
The antioxidant capacity of plasma, quantified as TEAC and
corrected for uric acid as major antioxidant in blood, tended to
increase by the 8 weeks MOF supplementation. However,
significant differences compared to the placebo group could not
be found (Figure 3A).
Circulating levels of the lipid peroxidation product 8-iso-PGF2a
were not affected by the 8 weeks supplementation with MOF
(Figure 3B).
Subjects allocated to the MOF group revealed 22% higher
GSH/GSSG concentrations in erythrocytes after 8 weeks
compared to baseline (P,0.05, Figure 3C). This increase appeared
to originate from a reduction in the GSSG quantities rather than
from a substantial increase in the amount of erythrocytes’ GSH
(data not shown).
No effect on the systemic expression of genes coding catalase
(CAT), glutathione peroxidase (GPX)1 and 4, glutathione
reductase (GSR), heme oxygenase 1 (HMOX1) and superoxide
dismutase 2 (SOD2) were observed in both groups (Figures S3A–
F). In the MOF group the expression of CAT, GSR and HMOX1
tended to decline after 8 weeks regarding baseline (Figures S3A,
5D, 5E).
Effects of the MOF supplementation on the VHI
The VHI is used to integrate the multiple effects monitored in
the present study. After 4 weeks the VHI tended to be higher in
the MOF group (mean 6 SD=62675) than in the placebo group
(mean 6 SD=235661, Figure 4A). The difference increased
after 8 weeks resulting in significantly higher VHI levels in the
MOF group (mean 6 SD=123647, P,0.05 vs. baseline)
compared to the placebo group (mean 6 SD=266679,
P#0.05, Figure 4B).
Discussion
The beneficial effects of food derived flavanols on vascular
health are becoming increasingly aware. However, the clinical
efficacy of these compounds in particular long-term is yet unclear
and limits their purposive application in daily medical practice.
The results of the present pilot study unveiled the potency of MOF
from Vitis vinifera L. to improve vascular health when regularly
applied for 8 weeks in relatively small amounts of 200 mg per day
in addition to the normal diet. The frequently observed positive
trends on single endpoints add up to a distinctive overall vascular
health benefit as indicated by a significantly higher vascular health
index compared to placebo.
In order to study health effects of dietary supplements the study
population, while generally healthy, should have or produce under
stress elevated levels of the relevant parameters. The disturbances
should be mild so that no pharmacological intervention is
required. The group of 28 smokers recruited in the present trial
fulfilled these criteria adequately. The majority of the volunteers
exhibited a number of established cardiovascular risk factors, e.g.
elevated serum total cholesterol and LDL [34] as well as slightly
increased CRP concentrations [34,36], but were neither diagnosed
with a vascular disease nor on cardiovascular medication. Notably,
the averaged endothelial function of smokers measured non-
invasively by means of brachial artery FMD at baseline (mean
FMD 6 SD=463%) was in good agreement with data from
Celermajer and colleagues who reported impaired macrovascular
function of smokers (mean FMD 6 SD=464%) compared to
age- and sex-matched non-smokers (mean FMD 6 SD=1063%)
[37]. Considering cardiovascular risk classification by the
Framingham Risk Scores [38] and by an approach based on
brachial artery FMD values [26], indicates that the healthy
subjects in our test groups might be at a moderate cardiovascular
risk.
Interestingly, it has been found that in a population at low
cardiovascular risk FMD values are inversely correlated with
cardiovascular risk, while in populations at intermediate or high
risk this correlation diminishes and disappears, respectively [26].
This phenomenon has been explained by the observation that
people with elevated cardiovascular risk possess a limited
distensibility of the brachial artery [39]. As a result FMD values
may not reflect any longer an exclusively endothelial NO
N-
mediated response. Irrespective from this aspect, evidence is
lacking yet that MOF may improve macrovascular function in
humans upon a long-term ingestion period, i.e. more than 4 weeks
[40]. Interestingly, dermal microvasculature became transiently
more sensitive to the endothelium-dependent stimulus ACh upon
4 weeks MOF intake. However, we cannot rule out that this effect
was due to chance, since after 8 weeks of intervention a similar
increase in sensitivity was observed in the placebo group.
Despite a wealth of animal studies demonstrating serum
cholesterol lowering effects of various mixtures of grape seed
flavanols, studies in humans are less conclusive [22,41]. Species
differences as well as variations in flavanolic composition might
result in altered clinical efficacy [42]. Our trial clearly emphasized
the potential of MOF to reduce hypercholesterolemia to a
significant and clinically relevant extent over an 8 weeks
consumption period. Although the cholesterol-lowering effects
were more pronounced after 4 than after 8 weeks, the median
LDL concentrations remained 0.2 mmol/L lower at the end of the
study compared to baseline. The same efficacy was reported for
green tea and soy protein isolate [41] and was estimated to reduce
all-cause mortality by 3% and CHD-related mortality and total
CHD events by 6% [43].
Moreover, our study showed a significant enhancement of the
smokers’ resistance against inflammatory stimuli, such as bacterial
endotoxin, upon the 8 weeks MOF supplementation. Remarkably,
MOF alleviated the inflammatory response in blood not only by
mitigating the LPS-induced secretion of the pro-inflammatory
cytokine TNF-a, but also by enhancing the release of the anti-
inflammatory cytokine IL-10. Likewise we could demonstrate that
the MOF-mediated increase in systemic inflammatory resistance
extends in humans to the modulation of the gene expression of
inflammatory cytokines, in particular TNF-a, IL-6 and IL-10.
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28460Figure 2. Changes from baseline in median (10
th to 90
th percentile) cytokine concentrations released upon LPS-addition (100 ng/
mL) to subjects’ blood ex vivo after 4 and 8 wk supplementation with either 200 mg/d monomeric and oligomeric flavanols (MOF,
n=15) or placebo (n=13): (A) TNF-a, percentage change; (B) IL-10, percentage change; (C) ratio of TNF-a to IL-10, absolute change.
Within-group changes were appraised by Wilcoxon Signed Ranks test, between-group changes by Mann-Whitney U test;
*Significantly different from
baseline in the same group, P,0.05.
#Significant difference between groups at the same time, P,0.05.
doi:10.1371/journal.pone.0028460.g002
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th and 90
th percentile) (box and whiskers) antioxidant capacity of plasma measured as
trolox equivalent antioxidant capacity (TEAC) and corrected for uric acid plasma concentrations (A), ratio of glutathione (GSH) to
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isolated MOF with NF-kB-mediated gene expression [44], the
unaltered expression of the inhibitory subunit NFKBIA did not
indicate an effect on the NF-kB pathway by MOF. Additionally,
we could not detect significant changes in the gene expression of
adhesion molecules, which are also regulated by the transcription
factor NF-kB.
Smokers are known to exhibit elevated levels of oxidative stress,
which has been established among others as reduced antioxidant
status [45,46] as well as a rise in biomarkers for lipid peroxidation
such as F2 isoprostanes [11,47]. We thus determined the systemic
extra- and intracellular redox state of the smokers under MOF
supplementation by measuring TEAC in plasma, GSH/GSSG
concentrations in erythrocytes and gene expression levels of the
redox enzymes CAT, GPX1, GPX4, GSR, HMOX1 and SOD2
in blood. The trend of increasing plasma TEAC values and the
considerable augmentation of the GSH/GSSG ratio in erythro-
cytes indicate that MOF improve extra- and intracellular redox
status in the circulation. These effects, however, could not be
ascribed to alterations of gene expression of the most important
enzymatic antioxidant defense systems in circulatory white blood
cells as discussed above. The systemic oxidative stress levels
assessed as plasma concentrations of the lipid peroxidation marker
8-iso-PGF2a were unaffected upon the 8 weeks MOF intake.
Similarly, it has been reported that a daily ingestion of 1000 mg
grape seed polyphenols for 6 weeks did not lower plasma
isoprostane levels in hypertensive subjects.
Our study also revealed that chronic MOF consumption did not
affect ADP- and collagen stimulated platelet aggregation ex vivo.
Whereas platelet-inhibiting effects could be clearly proven in
humans upon ingestion of cocoa-related products [48], the clinical
evidence for MOF from Vitis vinifera L. is less clear and might be
related to a difference in polyphenolic composition and dose [48].
Moreover, experiments with isolated human platelets suggest that
grape seed extract inhibits aggregation only in quite high
concentrations (100 mg/L blood) [49], which fairly exceed plasma
levels achievable in vivo. A prothrombotic state has also been
associated with elevated fibrinogen plasma concentrations, typi-
cally occurring in smokers [50]. This glycoprotein has been
identified to promote plasma viscosity, platelet aggregation,
coagulation and inflammation, thereby fueling atherogenesis.
Therefore, agents that lower circulatory fibrinogen might be
valuable [51]. The 8 week MOF intervention, however, remained
ineffective in this respect.
In the past decade in vitro and in vivo studies unraveled several
molecular mechanisms of flavanols that are essential in the
beneficial mediation of their vascular effects. These mechanisms
comprise a reduction in arginase activity that may contribute
glutathione disulphide (GSSG) in erythrocytes (B) and 8-isoprostaglandine F2a (8-iso-PGF2a) plasma concentrations of subjects at
baseline (0 wk) and after 4 and 8 wk supplementation with either 200 mg/d monomeric and oligomeric flavanols (MOF, n=15) or
placebo (n=13). The insert displays for each of the parameter the changes from baseline after 4 and 8 weeks intervention. Within-group changes
were appraised by either one-tailed paired-samples t-test (bar plots) or Wilcoxon Signed Ranks test (box and whiskers plots), between-group changes
by either two-tailed independent samples t-test (bar plots) or Mann-Whitney U test (box and whiskers plots);
*Significantly different from baseline in
the same group, P,0.05. There were no significant differences between the MOF and the placebo group at the same time points.
doi:10.1371/journal.pone.0028460.g003
Figure 4. Mean ± SD vascular health index (VHI) of individual subjects after 4 (A) and 8 wk (B) supplementation with either
200 mg/d monomeric and oligomeric flavanols (MOF, n=15) or placebo (n=13). Within-group changes were appraised by one-tailed
paired-samples t-test, between-group changes by two-tailed independent samples t-test;
*Significantly different from baseline in the same group,
P,0.05.
#Significant difference between groups at the same time, P,0.05.
doi:10.1371/journal.pone.0028460.g004
Vascular Health Benefits of Flavanols
PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e28460among others to an increased endothelial NO
N level [52], as well as
a decline in plasma ET-1 concentration [53]. In the setting of our
clinical trial we could not find significant changes in plasma nitrate
and nitrite concentration measured as surrogate for endothelial
NO
N production [54], as well as in arginase activity in erythrocytes
and ET-1 plasma concentration.
Already during the screening of the volunteers we carefully
checked by means of an investigator-guided interview and a
suitable questionnaire the intake of coffee, tea and chocolate
containing drinks as well as the consumption of chocolate and
chocolate containing food products and alcoholic beverages,
including beer, red and white wine. Also the use of any vitamins
and/or food supplements, adherence to a vegetarian and vegan
diet, a regular (at least 3 times a day) eating pattern as well as
fluctuations in body weight were evaluated and had to comply
with the in- and exclusion criteria of the study (see Methods,
‘‘Subjects and study design’’). In this way we could exclude
beforehand extreme and unusual behaviors and recruit a quite
homogenous group of typical Dutch middle-aged men [55]. Since,
however, we neither used food frequency questionnaires to
determine the exact daily food intake before and during the study
nor measured plasma levels of relevant flavanol metabolites, we
could not accurately assess the total intake of theses compounds in
both test groups. The rational for imposing no restriction
regarding diet and lifestyle was, that in this way clinical data
were collected on the vascular health effects of a relatively low-
dose supplementation with MOF under real-life conditions.
Food scientists are facing the challenge to proof the clinical
efficacy of nutrients that modulate human physiology in a subtle
and non-specific manner [25]. In drug research, where the one-
target-one-hit concept is imperative, randomized clinical trials
with a well-defined single endpoint are the gold standard of
efficacy testing. However, a single endpoint neither sufficiently
reflects the multifarious nature of nutrients’ functions in humans
nor the complexity of pathomechanisms underlying virtually all
diseases.
Our study pioneered the implementation of a pragmatic
solution for this problem: Carefully select a representative panel
of markers that reflect the major relevant pathological aberrations
and integrate all measured effects into a global health index. This
concept is in particular elegant, since it can easily be applied to
practically any other field of diseases.
In conclusion, our integrative multi-biomarker approach proved
to be a sensitive and therefore powerful strategy to unveil the
pleiotropic benefit of an 8 weeks supplementation with 200 mg/d
MOF on vascular health in humans.
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